BridgeBio's Acoramidis Cuts Risk Within Weeks In Rare Heart Condition

benzinga.com/news/health-care/25/09/47918744/bridgebios-acoramidis-cuts-risk-within-weeks-in-rare-heart-condition

BridgeBio Pharma, Inc. (NASDAQ: BBIO) on Sunday presented data from the ATTRibute-CM study.
The study showed that acoramidis reduced cumulative cardiovascular outcomes, including cardiovascular mortality (CVM) or recurrent cardiovascular-related hospitalizations (CVH), within the first…

This story appeared on benzinga.com, 2025-09-29 14:42:14.
The Entire Business World on a Single Page. Free to Use →